Implantation of the Ventura interatrial shunt, while safe, does not improve clinical outcomes or prognosis in patients with HF and preserved LVEF.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Consultant ...

Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today the ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

The Adona implant represents the next-generation of shunt technology, designed for dynamic interatrial flow that can be modified based on patient-specific hemodynamic needs," said Dr. Singh ...

The acquisition will add the company’s new and minimally invasive Ventura interatrial shunt to the MedTech portfolio. The ...

This is the beginning of the double circulatory system. The sinus venosus has shifted to the right and empties into right atrium, which is completely separated from left atrium by a thin interatrial ...

V-Wave’s Ventura Interatrial Shunt (IAS) is an implantable device designed to decrease elevated left atrial pressure in congestive heart failure by creating a shunt between the left and right ...

a left-to-right interatrial shunt; trace-to-mild aortic insufficiency; a well-seated mitral valve prosthesis with no regurgitation and a mean transmitral gradient of 5 mm Hg; and a right ...

TCT 468: No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly-Reduced Ejection Fraction: Twelve-Month Outcomes From Multi-Center Pilot Feasibility Studies Receive the the latest ...

As such, Johnson & Johnson could immediately utilize their global distribution channels to expand V-Wave Ventura Interatrial Shunt product worldwide. Johnson & Johnson has been building up their ...